The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysis

By Ramey Dena R.   Watson Douglas J.   Yu Chang   Bolognese James A.   Curtis Sean P.   Reicin Alise S.  

Current Medical Research and Opinion, Vol. 21, Iss. 5, 2005-05 ,pp. : 715-722

Informa Healthcare

Access to resources Recommend Favorite

Use of gastroprotective agents and discontinuations due to dyspepsia with the selective cyclooxygenase-2 inhibitor etoricoxib compared with non-selective NSAIDs

By Watson D.J.   Bolognese J.A.   Yu C.   Krupa D.   Curtis S.  

Current Medical Research and Opinion, Vol. 20, Iss. 12, 2004-12 ,pp. : 1899-1908

Informa Healthcare

Access to resources Recommend Favorite

Gastroprotection in patients prescribed non-selective NSAIDs, and the risk of related hospitalization

By Koncz T. A.   Lister S. P.   Makinson G. T.  

Current Medical Research and Opinion, Vol. 24, Iss. 12, 2008-12 ,pp. : 3405-3412

Informa Healthcare

Access to resources Recommend Favorite

Gastrointestinal tolerability of NSAIDs in elderly patients: a pooled analysis of 21 randomized clinical trials with celecoxib and nonselective NSAIDs

By Mallen Sharon R.   Essex Margaret N.   Zhang Richard  

Current Medical Research and Opinion, Vol. 27, Iss. 7, 2011-07 ,pp. : 1359-1366

Informa Healthcare

Access to resources Recommend Favorite

The effects of COX-2 selective and non-selective NSAIDs on the initiation and progression of atherosclerosis in ApoE^−/− mice

By Metzner Julia   Popp Laura   Marian Claudiu   Schmidt Ronald   Manderscheid Christine   Renne Christoph   Fisslthaler Beate   Fleming Ingrid   Busse Rudi   Geisslinger Gerd   Niederberger Ellen  

Journal of Molecular Medicine, Vol. 85, Iss. 6, 2007-06 ,pp. : 623-633

Springer Publishing Company

Access to resources Recommend Favorite